Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y251

UPID:
HPSE_HUMAN

ALTERNATIVE NAMES:
Endo-glucoronidase; Heparanase-1

ALTERNATIVE UPACC:
Q9Y251; A9JIG7; C7F7I3; C7F7I4; E9PCA9; E9PGR1; Q53GE5; Q9UL39

BACKGROUND:
Heparanase, known for its enzymatic activity in cleaving heparan sulfate proteoglycans, significantly impacts extracellular matrix remodeling, cell migration, and angiogenesis. It operates under acidic conditions, indicative of its role in tumor progression and inflammation. Beyond its enzymatic functions, Heparanase influences cell adhesion, osteogenesis, and vascular endothelial growth factor (VEGF) mediated angiogenesis, underscoring its multifaceted biological roles.

THERAPEUTIC SIGNIFICANCE:
The multifunctional nature of Heparanase, encompassing ECM remodeling, angiogenesis, and cell migration, underscores its potential as a therapeutic target. Its critical involvement in pathological processes such as cancer metastasis and inflammation presents a compelling case for the development of Heparanase inhibitors as innovative therapeutic agents.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.